Abstract:Pannexin 1 (Panx1), a ubiquitously expressed ATP release membrane channel, has been shown to play a role in inflammation and blood pressure regulation. Panx1 channel function is inhibited by spironolactone, a frontline therapy for heart failure patients. Despite this, the function of Panx1 in cardiomyocytes and a possible role in heart failure has not yet been studied. To investigate if Panx1 is involved in the development of non-ischemic heart failure, we use an acute (14 day) model of adrenergic stimulation (isoproterenol) to induce non-ischemic heart failure in a novel mouse model we have generated with constitutive deletion of Panx1 in cardiomyocytes by crossing mice expressing loxP-flanked alleles of Panx1 to mice expressing Cre recombinase under the control of the cardiomyocyte specific MyHC6 promoter (Panx1 MyHC6-Cre ). Constitutive deletion of Panx1 in cardiomyocytes had no effect on heart function at baseline, but protected mice against isoproterenol-induced non-ischemic heart failure (15 mg/kg/day isoproterenol, i.p.). Panx1 MyHC6-Cre mice were protected from systolic and diastolic dysfunction and cardiac hypertrophy as measured by echocardiography and heart mass, respectively. Moreover, Panx1 MyHC6-Cre mice demonstrated decreased recruitment of immune cells (CD45 + ), particularly neutrophils (CD11b + , Ly6g + ) to the myocardium as measured by confocal microscopy and flow cytometry. In vitro , treatment of H9c2 rat myoblasts with isoproterenol led to Panx1-dependent release of ATP and Yo-Pro-1 uptake in a dose-dependent manner, as assessed by pharmacological blockade by spironolactone and siRNA-mediated knock-down of Panx1. These data demonstrate that that β-adrenergic stimulation in cardiomyocytes activates Panx1 channels and that Panx1 deficiency in cardiomyocytes protects against non-ischemic heart failure and the associated cardiac dysfunction at least in part by reducing immune cell recruitment. Taken together, our study provides evidence for Panx1 channel inhibition as a therapeutic approach to ameliorate cardiac dysfunction in heart failure patients.

Recent advances in the structure and activation mechanisms of metabolite-releasing Pannexin 1 channels

The research progress in the functions of pannexin

[The Properties and Research Methods of Pannexins].

Pannexin1 Channel Inhibitor (10panx) Protects Against Transient Focal Cerebral Ischemic Injury by Inhibiting RIP3 Expression and Inflammatory Response in Rats.

Human Pannexin 1 channel: Insight in structure–function mechanism and its potential physiological roles

Mechanisms of Pannexin 1 (PANX1) Channel Mechanosensitivity and Its Pathological Roles

Pannexin 1, a Large-Pore Membrane Channel, Contributes to Hypotonicity-Induced ATP Release in Schwann Cells.

Pannexin-1 Channels and Their Emerging Functions in Cardiovascular Diseases.

Cryo-EM Structure of Human Heptameric Pannexin 1 Channel

Structure of the full-length human Pannexin1 channel and insights into its role in pyroptosis

Pannexin1 channels-a potential therapeutic target in inflammation

Differential activation of mouse and human Panx1 channel variants

The C-terminal activating domain promotes Panx1 channel opening

Deacetylation as a receptor-regulated direct activation switch for pannexin channels

Structural Mechanisms for the Activation of Human Cardiac KCNQ1 Channel by Electro-Mechanical Coupling Enhancers

Targeting Pannexin-1 Channels: Addressing the 'Gap' in Chronic Pain

Connexin hemichannels and pannexin channels in toxicity: Recent advances and mechanistic insights

Dual role for pannexin 1 at synapses: regulating functional and morphological plasticity

Pannexin 1 Channels Control Cardiomyocyte Metabolism and Neutrophil Recruitment During Non-Ischemic Heart Failure

Abstract P2040: Pannexin 1 Activation Drives Neutrophil Recruitment In A Murine Model Of Non-ischemic Heart Failure Induced By Isoproterenol

The P2X<sub>1</sub>ion channel in platelet function